The Dutch Healthcare Institute is taking a cautious, phased approach to new obesity drugs, limiting access to patients with the highest disease burden. The move reflects concerns about evidence gaps, cost-effectiveness, and the growing pressure obesity treatments could place on the national healthcare budget.
Thailand is letting patients fill hospital prescriptions at registered pharmacies under a new initiative expected to save households 32 billion baht annually. Officials say the program will ease private-sector pricing pressure and improve drug access nationwide.
Novo Nordisk’s $10 billion takeover for Metsera has survived a Delaware court challenge from Pfizer but now faces federal scrutiny from the FTC.
Scilex Holding Company has announced an exclusive global license from Datavault AI to tokenize and monetize genomic, diagnostic, and therapeutic data ushering in a new digital framework for valuing real-world biotech assets. The agreement allows Scilex to use Datavault’s proprietary AI-driven platform to create a Biotech Exchange, a marketplace designed to securely trade and fund … Read more
Metsera’s board has deemed Novo Nordisk’s $10 billion bid superior to Pfizer’s, setting off a high-stakes bidding and legal battle amid the obesity-drug gold rush.
In a major policy moment, Lilly and Novo Nordisk are in active talks with U.S. officials to cap obesity drug prices, aligning political pressure with market strategy.
HRSA’s approval of eight manufacturers for its 340B Rebate Model Pilot signals a major pricing shift.
CMS’s payment modernization plan seeks to trim inefficiencies, curb wasteful spending in wound care, and realign value in Medicare reimbursement. Providers brace for tighter margins as policymakers hail a new era of cost discipline.
From October 27, 2025, patients in the Netherlands with spinal metastases or multiple myeloma can access bone cement injections.
Lepu Medical expands its biotech footprint through a licensing deal with Sidera Bio for MWN105, a triple-agonist drug targeting obesity and metabolic disorders, combining equity, milestone, and royalty gains in a global partnership.